CRISPR Therapeutics (CRSP)
(Delayed Data from NSDQ)
$56.22 USD
+0.55 (0.99%)
Updated May 17, 2024 04:00 PM ET
After-Market: $55.90 -0.32 (-0.57%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth B Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
CRSP 56.22 +0.55(0.99%)
Will CRSP be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for CRSP based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CRSP
Investors Heavily Search CRISPR Therapeutics AG (CRSP): Here is What You Need to Know
bluebird (BLUE) Tops on Q1 Sales, Zynteglo Progresses Well
CRSP: What are Zacks experts saying now?
Zacks Private Portfolio Services
CRISPR's (CRSP) Q1 Loss Narrower-Than-Expected, Sales Miss
CRISPR Therapeutics AG (CRSP) Reports Q1 Loss, Misses Revenue Estimates
Vertex's (VRTX) Q1 Earnings Beat, Trikafta Drives Sales
Other News for CRSP
Why Cathie Wood’s Ark Innovation ETF is struggling in 2024 despite the stock-market rally
BLUE vs. CRSP: Why Are These Stocks Moving in Opposite Directions?
Wall Street Favorites: 3 Biotech Stocks with Strong Buy Ratings for May 2024
CRSP, NYMT and SBRA are among after hour movers
Why Cathie Wood’s ARK Innovation ETF is struggling in 2024 despite the stock-market rally